EFTA00845182.pdf

From: Richard Kahn < To: Jeffrey Epstein <[email protected]> Subject: FW: Series 8 Investment to Cover Common Investment Date: Sat, 26 Sep 2015 16:21:29 +0000 Attachments: Jawbone_Mort_investment_analysis_2015-09-18.pdf; UP2_&_UP3_Launch_Summary.pdf Please advise From: Richard Kahn S-• Date: Friday, September 18, 2015 at 9:51 PM To: Jeffrey Epstein <[email protected]> Subject: Fwd: Series 8 Investment to Cover Common Investment Andrew called this afternoon and asked if we were going to participate in series 8. I expressed our displeasure that our entire investment could not be protected. He then said that is not true. I said this is now the third time they are changing fact pattern. He prepared attached summary for your review. He said they have 33.5 of 35mm to force black rock to invest final 50mm. Please advise if you have any interest in investing. Thank you. Richard Kahn HBRK Associates Inc. 575 Lexington Avenue, 4th Floor New York, NY 10022 Tel Fax Cel Begin forwarded message: From: Andrew Lindsay Date: September 18, 2015 at 9:27:27 PM EDT To: Richard Kahn < Cc: Anna Podkovyrova Subject: Series 8 Investment to Cover Common Investment Hi Rich, It was great chatting with you this morning. As I noted, Mort can make an investment in Series 8 to have enough liquidation preference to cover both its common and preferred investments. With an investment of just $1.25M in Series 8 will result in Mort having a resulting total liquidation preference of $11.25M, to cover the previous $5M of common, $5M of preferred and new $1.25M investments. In addition to the increased liquidation preference, for the $1.25M, Mort will also receive an incremental 677,244 shares with all the upside of Jawbone equity. That equates to $1.85 per share. Detail of the structure is included in the attached document. I've also included a summary of the successful launch of our recent UP2 and UP3 products. It's been very well received with reviews like this. EFTA00845182  Thanks, Andrew From: Richard Kahn Date: Thursday, September 17, 2015 at 4:33 PM To: Jeffrey Epstein <[email protected]> Subject: Jawbone i spoke with Andrew Linsey, Anna and Will from Code Advisors as Hosain was unavailable last week only 5,000,000 of investment would be covered as this can only apply to preferred shares our investment in Series S was as follows: Preferred 695,301 x 7.19113 = 5,000,000 Common 1,260,233 x 3.96792 = 5,000,000 I was told on call that valuation of company at time of Series S was 1,650,000 post Series 6, 7, 8 and Blackrock note have further diluted our investment and although they would not give me an exact figure our new breakeven without Series 8 participation appears to be 3,250,000 With Series 8 investment of 833,000 i believe believe we would receive the following on a sale of company post April 28 2016 1,000,000 7,500,000 from preferred and 0 from common (0 received without Series 8) 2,000,000 7,500,000 from preferred and 0 from common (0 received without Series 8) 3,000,000 7,500,000 from preferred and 0 from common (0 received without Series 8) 3,250,000 7,500,000 from preferred and 5,000,000 from common (10,000,000 received without Series 8) it appears Series 8 protection provides protection from 1,000,000 to 3,250,000 on liquidation April 28 2016 is key date as it is 1 year anniversary of Blackrock investment and if company sold before that date they have a 3x liquidation preference As of last friday they have raised 33,000,000 of the 35,000,000 needed for Blackrock to release final 50,000,000 If that is achieved they would have raised since April 28 2015: 220,000,000 Blackrock original note 40,000,000 Series 8 JPM (34) and Sequia (6) 50,000,000 Blackrock additional 35,000,000 Series 8 (33mm raised to date) 50,000,000 Blackrock final 395,000,000 Total raised As of Sep 11, 2015 there cash flow was as follows: 30,000,000 in cash 85,000,000 (Series 8 and final Blackrock) 115,000,000 potential cash Once 85,000,000 is secured they will finalize deal for an ABL credit line in the amount of 50,000,000 that will be collateralized by AR and Inventory EFTA00845183 They mentioned that Q4 would be cash flow positive however they did not elaborate on what their loss for 2015 or 2016 would be.. When i pressed them and said i thought they would would be out of money by mid 2016 and we again may be further diluted with a Series 9 or 10 they responded that they had new management that would not allow this They said Jason Child, new CFO, has already run analysis to ensure that they remain cash flow positive in 2016 Not sure that is so realistic as they also mentioned that Fitbit already has market share and that they will not chase market share via lower pricing or marketing In addition they will not build large inventories with vendors if they need to conserve cash Andrew stated that Hosain made poor non financially focused decisions and new CFO will not allow that moving forward Jawbone believes it will be the leader in the next phase which will evolve from basic wellness to health and medical (blood pressure, respiration and oxidation) Analogy was used that basic wellness market is similar to Smartphones in the early 2000's and Symbian who was leader disappeared My concerns are as follows: a) Jawbone is always one step behind and they keep jumping to the next Hot idea.. b) There will inevitably be a Series 9 / 10 round as i believe they will again run out of cash middle of next year causing further dilution to Series 8 they are asking us to participate in Andrew also sent email with codes for free UP 2 or UP 3 product I will order and have for you on your next visit (do you have a color preference - black, silver, indigo and red?) http://www.amazon.com/UP3-Jawbone-Activity-Tracker-Black/dp/B00N9E6DUK/ref=sr 1 1?ie=UTF8&qid=1442521265&sr=8- l&keywords=up3 Please advise how you want to proceed with Series 8 proposed investment of 833,000 Thank you Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York, NY 10022 tel fax cell On Sep 17, 2015, at 2:38 PM, jeffrey E. <[email protected]> wrote: did you check with hosssain re amount of investment covered please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of EFTA00845184 JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected] and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00845185